Use of Hydroxychloroquine and Chloroquine During the COVID-19 Pandemic: What Every Clinician Should Know

Ann Intern Med. 2020 Jun 2;172(11):754-755. doi: 10.7326/M20-1334. Epub 2020 Mar 31.


Two medications often used for treatment of immune-mediated conditions, hydroxychloroquine and chloroquine, have recently attracted widespread interest as potential therapies for coronavirus disease 2019. The authors of this commentary provide guidance for clinical decision making for patients with coronavirus disease 2019 as well as for patients with rheumatologic conditions, such as systemic lupus erythematosus and rheumatoid arthritis

Keywords: Antimalarials; Blood plasma; COVID-19; Chloroquine; Clinical trials; Decision making; Drugs; Lupus erythematosus; Metastasis; Pulmonary diseases.

Publication types

  • Editorial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Betacoronavirus
  • COVID-19
  • COVID-19 Drug Treatment
  • Chloroquine / supply & distribution
  • Chloroquine / therapeutic use*
  • Coronavirus Infections / drug therapy*
  • Drug Repositioning
  • Humans
  • Hydroxychloroquine / supply & distribution
  • Hydroxychloroquine / therapeutic use*
  • Pandemics
  • Pneumonia, Viral / drug therapy*
  • Randomized Controlled Trials as Topic
  • Rheumatic Diseases / drug therapy*
  • SARS-CoV-2


  • Hydroxychloroquine
  • Chloroquine